AstraZeneca oncology R&D chief Susan Galbraith: ‘You’re going to need orthogonal combinations’

 

Earlier in the week we broadcast our 4th annual European Biopharma Summit with a great lineup of top execs. One of the one-on-one conversations I set up was with Susan Galbraith, the oncology research chief at AstraZeneca. In a wide-ranging discussion, Galbraith reviewed the cancer drug pipeline and key...

Click to view original post